Evaluation of the efficacy and safety of FOLFIRINOX or albumin-bound paclitaxel in combination with S-1 in patients with pancreatic cancer

International Journal of Industrial Chemistry

دوره 13، شماره 1، خرداد 2022، صفحه 12-19   

نوع مقاله: research article

شناسه دیجیتال (DOI): 10.47176/IJIC.13.1.2

نویسندگان

Luan Li¹؛ Yuxu Feng²؛ Chenchen Li¹؛ Siwen Liu¹؛ Fei Yan¹؛ Jingni Zhu¹؛ Xiaoyou Li^{* 3}؛ Sheng Li¹

¹Department of Medical Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China

²Department of Orthopaedics, Pukou Central Hospital, PuKou Branch Hospital of Jiangsu Province Hospital, Nanjing, Jiangsu, People’s Republic of China

³Department of Medical Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China

چکیده

To investigate the clinical efficacy and safety of FOLFIRINOX or albumin-bound paclitaxel (Abraxane) combined with S-1 after radical pancreatic cancer surgery.
A total of 133 patients who underwent adjuvant chemotherapy with the FOLFIRINOX (60 cases) or Abraxane combined with S-1 (73 cases) after radical resection pancreatic cancer were screened. According to the follow-up data, recurrence and metastasis, chemotherapy adverse reactions (nausea, vomiting, loss of appetite, leukopenia, thrombocytopenia, anemia, neurotoxicity, diarrhea), survival rate (OS), progression-free survival (PFS) and other indicators were collected to evaluate the efficacy and safety of the two chemotherapy regimens.
There was significant difference of metastatic tumor site between both groups (P<0.001). The cases of DCR in the Abraxane + S-1 group were higher compared to the FOLFIRINOX group (P<0.001). The occurrence of adverse events was significantly lower in Abraxane + S-1 group during I-II AE compared with the FOLFIRINOX group. However, there was no significant difference in the AE during III-IV between two groups (P>0.05). The OS (HR=1.872, P=0.005) and PFS (HR=1.931, P=0.003) in Abraxane + S-1 group were significantly higher than those in the FOLFIRINOX group.
Adjuvant chemotherapy with Abraxane combined with S-1 regimen in patients with pancreatic cancer resection prolonged OS and PFS, improved DCR, with the overall adverse reactions safe and manageable compared with the FOLFIRINOX regimen.

کلیدواژه‌ها

FOLFIRINOX؛ albumin-bound paclitaxel؛ S-1؛ pancreatic cancer